Regen BioPharma, Inc. (RGBP)

OTCMKTS · Delayed Price · Currency is USD
0.0009
0.00 (0.00%)
Mar 6, 2026, 1:57 PM EST
-98.36%
Market Cap 178.35K
Revenue (ttm) 236.56K
Net Income (ttm) -1.73M
Shares Out 212.32M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,209,400
Average Volume 9,109,421
Open 0.0010
Previous Close 0.0009
Day's Range 0.0008 - 0.0010
52-Week Range 0.0009 - 0.1169
Beta 2.76
RSI 29.47
Earnings Date Apr 17, 2026

About Regen BioPharma

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxy... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol RGBP
Full Company Profile

Financial Performance

In fiscal year 2025, Regen BioPharma's revenue was $236,561, an increase of 0.00% compared to the previous year's $236,560. Losses were -$1.27 million, 90.7% more than in 2024.

Financial Statements

News

There is no news available yet.